The therapeutic potential of a kallikrein inhibitor for treating hereditary angioedema

Bibliography

• BOWEN T, CICARDI M, FARKAS H et al.: Canadian 2003 international consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. J. Allergy Clin. Immunol. (2004) 114:629-637.
   PubMed Web of Science ®Google Scholar
• AGOSTONI A, AYGOREN-PURSUN E, BINKLEY KE et al.: Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J. Allergy Clin. Immunol. (2004) 114:S51-131.
   PubMed Web of Science ®Google Scholar
• CICARDI M, BERGAMASCHINI L, CUGNO M et al.: Pathogenetic and clinical aspects of C1 inhibitor deficiency. Immunobiology (1998) 199:366-376.
   PubMed Web of Science ®Google Scholar
• BORK K, HARDT J, SCHICKETANZ KH, RESSEL N: Clinical studies of sudden upper airway obstruction in patients with hereditary angioedema due to C1 esterase inhibitor deficiency. Arch. Intern. Med. (2003) 163:1229-1235.
   PubMed Web of Science ®Google Scholar
• ROCHE O, BLANCH A, CABALLERO T et al.: Hereditary angioedema due to C1 inhibitor deficiency: patient registry and approach to the prevalence in Spain. Ann. Allergy Asthma Immunol. (2005) 94:498-503.
   PubMed Web of Science ®Google Scholar
• FRANK MM: Urticaria and angioedema. In: Goldman: Cecil textbook of medicine. Goldman L, Ausiello D (Eds), WB Saunders Co., Philadelphia, USA (2004) 22:1613.
   Google Scholar
• TOSI M: Molecular genetics of C1 inhibitor. Immunobiology (1998) 199:358-365.
   PubMed Web of Science ®Google Scholar
• DAVIS AE: C1 inhibitor and hereditary angioneurotic edema. Ann. Rev. Immunol. (1988) 6:595-628.
   PubMed Web of Science ®Google Scholar
• AGOSTONI A, CICARDI M: Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients. Medicine (1992) 71:206-215.
   PubMed Web of Science ®Google Scholar
• BRICKMAN CM, TSOKOS GC, CHUSED TM et al.: Immunoregulatory disorders associated with hereditary angioedema. II. Serologic and cellular abnormalities. J. Allergy Clin. Immunol. (1986) 77:758.
   PubMed Web of Science ®Google Scholar
• DAVIS AE: The pathophysiology of hereditary angioedema. Clin. Immunol. (2005) 114:3-9.
   PubMed Web of Science ®Google Scholar
• LEHMANN A: Ecallantide. Curr. Opin. Invest. Drugs (2006) 7(3):282-290.
   PubMed Web of Science ®Google Scholar
• WILLIAMS A, BAIRD LG: DX-88 and HAE: a developmental perspective. Transfus. Apher. Sci. (2003) 29:255-258.
   PubMed Web of Science ®Google Scholar
• WILLIAMS T, SCHNEIDER L, LUMRY W, VEGH A: DX-88: a double blind placebo controlled study in hereditary angioedema (HAE) the EDEMA1 study. 2004 Annual Meeting of the American College of Allergy, Asthma and Immunology, Boston, USA (2004):38.
   Google Scholar
• SILVERBERG M, REDDIGARI SR, KAPLAN AP: The contact system and its disorders. In: Blood: Principles & Practice of Hematology. Handin RI, Lux SE, Stossel RP (Eds), JB Lippincott Co., Philadelphia, USA (1995):1127-1150.
   Google Scholar
• GREAVES M, LAWLOR F: Angioedema: manifestations and management. J. Am. Acad. Derm. (1991) 25:155-161.
   PubMed Web of Science ®Google Scholar
• BORK K, RISCHER B, DEWALD G: Recurrent episodes of skin angioedema and severe attacks of abdominal pain induced by oral contraceptives or hormone replacement therapy. Am. J. Med. (2003) 114:294-298.
   PubMed Web of Science ®Google Scholar
• MALBRAN A, HAMMER CH, FRANK MM, FRIES LF: Acquired angioedema: observations on the mechanism of action of autoantibodies directed against C1 esterase inhibitor. J. Allergy Clin. Immunol. (1998) 81:1199-1204.
   Google Scholar
• VLEEMING W, VAN AMSTERDAN JG, STRICKER BH, DE WILDT DJ: ACE inhibitor-induced angioedema. Incidence, prevention and management. Drug Saf. (1998) 18:171-88.
   PubMed Web of Science ®Google Scholar
• PAVLETIC A: Late angioedema caused by ACE Inhibitors underestimated. Am. Fam. Physician (2002) 66:956-958.
   PubMed Web of Science ®Google Scholar
• MOLINARO G, CUGNO M, PEREZ M et al.: Angiotensin-converting enzyme inhibitor-associated angioedema is characterized by a slower degradation of des-arginine(9)-bradykinin. J. Pharmacol. Exp. Ther. (2002) 303:232-237.
   PubMed Web of Science ®Google Scholar
• ZANCHI A, MAILLARD M, BURNIER M: Recent clinical trials with omapatrilat: new developments. Curr. Hypertens. Rep. (2003) 5:346-352.
   PubMed Web of Science ®Google Scholar
• SIM RB, ARLAUD GJ, COLOMB MG: C1 inhibitor-dependent dissociation of human complement component C1 bound to immune complexes. Biochem. J. (1979) 179(3):449-457.
   PubMed Web of Science ®Google Scholar
• OLTVAI ZN, WONG ECC, ATKINSON JP, TUNG KS: C1 inhibitor deficiency: molecular and immunologic basis of hereditary and acquired angioedema. Lab. Invest. (1991) 65:381-388.
   PubMed Web of Science ®Google Scholar
• DAVIS AE: The pathogenesis of hereditary angioedema. Transfus. Apher. Sci. (2003) 29:195-203.
   PubMed Web of Science ®Google Scholar
• PETERSEN SV, THIEL S, JENSEN L, VORUP-JENSEN T, KOACH C, JENSENIUS JC: Control of the classical and the MBL pathway of complement activation. Mol. Immunol. (2000) 37(14):803-811.
   PubMed Web of Science ®Google Scholar
• JIANG H, WAGNER E, ZHANG H, FRANK MM: Complement 1 inhibitor is a regulator of the alternative complement pathway. J. Exp. Med. (2001) 194(11):1609-1616.
   PubMed Web of Science ®Google Scholar
• ZICCARDI RJ: Activation of the early components of the classical complement pathway under physiologic conditions. J. Immunol. (1981) 126:1769-1773.
   PubMed Web of Science ®Google Scholar
• DE AGOSTINI A, LIJNEN HR, PIXLEY RA, COLMAN RW, SCHAPIRA M: Inactivation of factor-XII active fragment in normal plasma: predominant role of C1-inhibitor. J. Clin. Invest. (1984) 73(6):1542-1549.
   PubMed Web of Science ®Google Scholar
• SHAPIRA M, SCOTT CF, COLMAN RW: Contribution of plasma protease inhibitors to the inactivation of kallikrein in plasma. J. Clin. Invest. (1992) 69:462-468.
   Google Scholar
• VAN DER GRAAF F, KOEDAM JA, BOUMA BN: Inactivation of kallikrein in human plasma. J. Clin. Invest. (1983) 71:149-158.
   PubMed Web of Science ®Google Scholar
• SHARIAT-MADAR Z, MAHDI F, SCHMAIER AH: Identification and characterization of prolylcarboxypeptidase as an endothelial cell prekallikrein activator. J. Biol. Chem. (2002) 277:17962.
   PubMed Web of Science ®Google Scholar
• JOSEPH K, KAPLAN AP: Formation of bradykinin: a major contributor to the innate inflammatory response. Adv. Immunol. (2005) 86:159-208.
   PubMed Web of Science ®Google Scholar
• BAUER K: Hypercoagulable states. In: Hematology: basic principles and practice. Hoffman R (Ed.), Churchill Livingstone, Philadelphia, USA (2005) 4:2209.
   Google Scholar
• CYR M, LEPAGE Y, BLAIS C et al.: Bradykinin and des-Arg9-bradykinin metabolic pathways and kinetics of activation in human plasma. Am. J. Physiol. Heart Circ. Physiol. (2001) 281:H275-H283.
   PubMed Web of Science ®Google Scholar
• KAPLAN AP, GHEBREHIWET B: Does C-2 kinin exist? J. Allergy Clin. Immunol. (2005) 115:876.
   PubMedGoogle Scholar
• ZAHEDI R, BISSLER JJ, DAVIS AE, ANDREADIS C, WISNIESKI JJ: Unique C1 inhibitor dysfunction in a kindred without angioedema. II. Identification of an Ala443-Val substitution and functional analysis of the recombinant mutant protein. J. Clin. Invest. (1995) 95:1299-1305.
   PubMed Web of Science ®Google Scholar
• JUHLIN L, MICHAELSSON G: Vascular reactions in hereditary angioedema. Acta Derm. Venereal. (1969) 49:20.
   PubMed Web of Science ®Google Scholar
• CURD JG, YELVINGTON M, BURRIDGE N et al.: Generation of bradykinin during incubation of hereditary angioedema plasma. Mol. Immunol. (1982) 19:1365.
   Google Scholar
• CURD JG, PROGRAIS LJ, COCHRANE CG: Detection of active kallikrein in induced blister fluids of hereditary angioedema patients. J. Exp. Med. (1980) 152:742-747.
   PubMed Web of Science ®Google Scholar
• FIELDS T, GHEBREWIHET B, KAPLAN A: Kinin formation in hereditary angioedema plasma: evidence against kinin derivation from C2 and in support of spontaneous formation of bradykinin. J. Allergy Clin. Immunol. (1983) 72:54-60.
   PubMed Web of Science ®Google Scholar
• SHOEMAKER LR, SCHURMAN SJ, DONALDSON VH, DAVIS AE: Hereditary angioneurotic edema: characterization of plasma kinin and vascular permeability-enhancing activities. Clin. Exp. Immunol. (1994) 95:22-28.
   PubMed Web of Science ®Google Scholar
• CUGNO M, NUSSBERGER J, CICARDI M, AGOSTONI A: Bradykinin and the pathophysiology of angioedema. Inter. Immunopharm. (2003) 3(3):311-317.
   PubMed Web of Science ®Google Scholar
• NUSSBERGER J, CUGNO M, AMSTUTZ C et al.: Plasma bradykinin in angioedema. Lancet (1998) 351:1693-1697.
   PubMed Web of Science ®Google Scholar
• NUSSBERGER J, CUGNO M, CICARDI M: Bradykinin-mediated angioedema. N. Engl. J. Med. (2002) 347:621-622.
   PubMed Web of Science ®Google Scholar
• NUSSBERGER J, CUGNO M, CICARDI M, AGOSTONI A: Local bradykinin generation in hereditary angioedema. J. Allergy Clin. Immunol. (1999) 104(6):1321-1322.
   PubMed Web of Science ®Google Scholar
• HAN ED, MacFARLANE RC, MULLIGAN AN, SCAFIDI J, DAVIS AE: Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. J. Clin. Invest. (2002) 109(8):1057-1063.
   PubMed Web of Science ®Google Scholar
• CICARDI M, AGOSTONI A: Hereditary angioedema. N. Engl. J. Med. (1996) 334:1666-1667.
   PubMed Web of Science ®Google Scholar
• LONGHURST HJ: Emergency treatment of acute attacks in hereditary angioedema due to C1 inhibitor deficiency: what is the evidence? Int. J. Clin. Pract. (2005) 59:594-599.
   PubMed Web of Science ®Google Scholar
• WINNEWISSER J, ROSSI M, SPATH P, BURGI H: Type I hereditary angio-edema. Variability of clinical presentation and course within two large kindreds. J. Intern. Med. (1997) 241(1):39-46.
   PubMed Web of Science ®Google Scholar
• GOMPELS MM, LOCK RJ, ABINUN M et al.: C1 Inhibitor deficiency: consensus document. Clin. Exp. Immunol. (2005) 139(3):379-394.
   PubMed Web of Science ®Google Scholar
• SIM TC, GRANT JA: Hereditary angioedema: its diagnostic and management perspectives. Am. J. Med. (1990) 88(6):656-664.
   PubMed Web of Science ®Google Scholar
• GELFAND JA, SHERINS RJ, ALLING DW, FRANK MM: Treatment of hereditary angioedema with danazol: reversal of clinical and biochemical abnormalities. N. Engl. J. Med. (1976) 295(26):1444-1448.
   PubMed Web of Science ®Google Scholar
• GADEK JE, HOSEA SW, GELFAND JA, FRANK MM: Response of variant hereditary angioedema phenotypes to danazol therapy. Genetic implications. J. Clin. Invest. (1979) 64(1):280-286.
   PubMed Web of Science ®Google Scholar
• CICARDI M, CASTELLI R, ZINGALE LC, AGOSTONI A: Side effects of long-term prophylaxis with attenuated androgens in hereditary angioedema: comparison of treated and untreated patients. J. Allergy Clin. Immunol. (1997) 99(2):194-196.
   PubMed Web of Science ®Google Scholar
• BORK K, PITTON M, HARTEN P, KOCH P: Hepatocellular adenomas in patients taking danazol for hereditary angio-edema. Lancet (1999) 353(9158):1066-1067.
   PubMed Web of Science ®Google Scholar
• RITCHIE BC: Protease inhibitors in the treatment of hereditary angioedema. Transfus. Apher. Sci. (2003) 29(3):259-267.
   PubMed Web of Science ®Google Scholar
• WALLACE EM, PERKINS SJ, SIM RB, WILLIS AC, FEIGHERY C, JACKSON J: Degradation of C1-inhibitor by plasmin: implications for the control of inflammatory processes. Mol. Med. (1997) 3:385-396.
   PubMed Web of Science ®Google Scholar
• FRANK MM, SERGENT JS, KANE MA, ALLING DW: Epsilon aminocaproic acid therapy of hereditary angioneurotic edema: a double blind study. N. Engl. J. Med. (1976) 295:1444-1448.
   PubMed Web of Science ®Google Scholar
• CICARDI M, ZINGALE L: How do we treat patients with hereditary angioedema. Transfus. Apher. Sci. (2003) 29(3):221-227.
   PubMed Web of Science ®Google Scholar
• ZURAW BL: Diagnosis and management of hereditary angioedema: an American approach. Transfus. Apher Sci. (2003) 29(3):239-245.
   PubMed Web of Science ®Google Scholar
• BORK K, WITZKE G: Long term prophylaxis with C1-inhibitor concentrate with recurrent angioedema caused by hereditary and acquired C1-inhibitor deficiency. J. Allergy Clin. Immunol. (1989) 83:677-682.
   PubMed Web of Science ®Google Scholar
• BORK K, MENG G, STAUBACH P, HARDT J: Treatment with C1 inhibitor concentrate in abdominal pain attacks of patients with hereditary angioedema. Transfusion (2005) 45:1774-1784.
   PubMed Web of Science ®Google Scholar
• LONGHURST HJ: Emergency treatment of acute attacks in hereditary angioedema due to C1 inhibitor deficiency: what is the evidence? Int. J. Clin. Pract. (2005) 59:594-599.
   PubMed Web of Science ®Google Scholar
• GADEK JE, HOSEA SW, GELFAND JA et al.: Replacement therapy in hereditary angioedema: successful treatment of acute episodes of angioedema with partly purified C1 inhibitor. N. Engl. J. Med. (1980) 302:542-546.
   PubMed Web of Science ®Google Scholar
• DE SERRES J, GRONER A, LINDNER J: Safety and efficacy of pasteurized C1 inhibitor concentrate (Berinert P) in hereditary angioedema: a review. Transfus. Apher. Sci. (2003) 29:247-254.
   PubMed Web of Science ®Google Scholar
• WAYTES AT, ROSEN FS, FRANK MM: Treatment of hereditary angioedema with a vapor-heated C1 Inhibitor concentrate. N. Engl. J. Med. (1996) 334:1630-1634.
   PubMed Web of Science ®Google Scholar
• KUNSCHAK M, ENGL W, MARITSCH F et al.: A randomized, controlled trial to study the efficacy and safety of C1 inhibitor concentrate in treating hereditary angioedema. Transfusion (1998) 38(6):540-549.
   PubMed Web of Science ®Google Scholar
• BERGAMASCHINI L, CICARDI M: Recent advances in the use of C1 inhibitor as a therapeutic agent. Mol. Immunol. (2003) 40:155-158.
   PubMed Web of Science ®Google Scholar
• FRANK M: Hereditary angioedema: a half century of progress. J. Allergy Clin. Immunol. (2004) 114:626-628.
   PubMed Web of Science ®Google Scholar
• MARKLAND W, LEY AC, LADNER RC: Iterative optimization of high-affinity protease inhibitors using phage display. 2. Plasma kallikrein and thrombin. Biochemistry (1996) 35(24):8058-8067.
   PubMed Web of Science ®Google Scholar
• LEY AC, MARKLAND W, LADNER RC: Obtaining a family of high-affinity, high specificity protein inhibitors of plasmin and plasma kallikrein. Mol. Divers. (1996) 2:119-124.
   PubMed Web of Science ®Google Scholar
• NIXON AE: Use of phage display to identify potent and specific protease inhibitors. 18th American Peptide Symposium on Peptide Revolution: Genomics, Proteomics and Therapeutics, Boston, USA (2003):0719.
   Google Scholar
• DSEXTON: DX-88 protease specificity measurements. Version 1. Unpublished Dyax internal data, on file (2006).
   Google Scholar
• WIMAN B: Human C1-inhibitor. In: Proteinase Inhibitors. Barrett AJ, Salvesen G (Eds), Elsevier, New York, USA (1990):477-488.
   Google Scholar
• PIXLEY RA, SCHAPIRA M, COLMAN RW: The regulation of human Factor XIIa by plasma proteinase inhibitors. J. Biol. Chem. (1985) 260:1723-1729.
   PubMed Web of Science ®Google Scholar
• WIMAN B, NILSSON T: kinetics of the reaction between human C1-esterase inhibitor and C1r or C1s. Eur. J. Biochem. (1983) 129:663-667.
   PubMedGoogle Scholar
• SCHAPIRA M, SCOTT CF, COLMAN RW: Protection of human plasma kallikrein from inactivation by C1 inhibitor and other protease inhibitors. The role of high molecular weight kininogen. Biochemistry (1981) 20(10):2738-2743.
   PubMed Web of Science ®Google Scholar
• WUILLEMIN WA, ELDERING E, CITARELLA F, DE RUIG CP, CATE H, HACK CE: Modulation of contact system proteases by glycosaminoglycans. Selective enhancement of the inhibition of factor XIa. J. Biol. Chem. (1996) 271(22):12913-12918.
   PubMed Web of Science ®Google Scholar
• GUNAWARDENA K: An open-label study of the pharmacokinetic and safety profiles of subcutaneous versus intravenous formulations of ecallantide (DX-88), a potent recombinant protein inhibitor of human plasma kallikrein. Annual Meeting of the American College of Asthma, Allergy and Immunology, Anaheim, USA (2005) (Booth 1029).
   Google Scholar
• IAN J, LAWRIE AS, PURDY G, WILLIAMS T, MACHIN SJ: DX-88, a novel kunitz-type inhibitor of human plasma kallikrein with potential therapeutic use. 44th Annual Meeting of the American Society of Hematology, Philadelphia, USA (2002):3892 (Abstract).
   Google Scholar
• CICARDI M, GONZALEZ-QUEVEDO T, CABALLERO T, BORK K, WILLIAMS A: DX-88 a recombinant inhibitor of human plasma kallikrein. Efficacy and safety in hereditary and acquired angioedema. 9th European Complement Workshop, Trieste, Italy (2003):0906.
   Google Scholar
• GONZALEZ-QUEVEDO T, CICARDI M, BORK K, WILLIAMS A: The synthetic Kunitz domain protein DX88 to treat angioedema in patients with hereditary angioedema. XIX International Complement Workshop, Palermo, Italy (2002):0922.
   Google Scholar
• WILLIAMS T, CICARDI M, BORK K, GONZALEZ-QUEVEDO T, CABELLERO T: DX-88, a recombinant inhibitor of human plasma kallikrein. Evaluation of efficacy and safety in patients with hereditary angioedema. 60th Aniversary Meeting of the American Academy of Allergy, Asthma and Immunology, Denver, USA (2003):L3.
   Google Scholar
• DEVERAS RA, BRACHO F: Inhibitor of human plasma kallikrein DX-88 for the treatment of acute attack in a family with hereditary angioedema. 46th Annual Meeting of the American Society of Hematology, San Diego, USA (2004):4109.
   Google Scholar
• LUMRY W, RITCHIE B, BECK T, MORRISON J: Interim results of EDEMA2, a multicenter, open-label, repeat dosing study of intravenous and subcutaneous administration of ecallantide (DX-88) in hereditary angioedema. J. Allergy Clin. Immunol. (2006) 117(2S):S179 (Abstract).
   Web of Science ®Google Scholar
• LI HH, SCHNEIDER L, CRAIG T, LUMRY W, BECK T: Repeat dosing of IV and SC formulations of DX-88, a highly potent inhibitor of human plasma kallikrein for the treatment of patients with hereditary angioedema. XXV Congress of the European Academy of Allergology and Clinical Immunology, Vienna, Austria (2006) (In Press).
   Google Scholar
• POLK RE: Anaphylactoid reactions to gylcopeptide antibiotics. J. Antimicrob. Chemother. (1991) 27(Suppl. B):17-29.
   PubMed Web of Science ®Google Scholar
• LEVY M, KOREN G, DUPUIS L, READ SE: Vancomycin-induced red man syndrome. Pediatrics (1990) 86(4):572-580.
   PubMed Web of Science ®Google Scholar
• LIEBE V, BRUCKMANN M, FISCHER KG, HAASE KK, BORGGREFE M, HUHLE G: Biological relevance of anti-recombinant hirudin antibodies – results from in vitro and in vivo studies. Semin. Thromb. Hemost. (2002) 28(5):483-490.
   PubMed Web of Science ®Google Scholar
• ANTONELLI G, BAGNATO F, POZZILLI C et al.: Development of neutralizing antibodies in patients with relapsing-remitting multiple sclerosis treated with IFN-β1a. J. Interferon Cytokine Res. (1998) 18:345–350.
   PubMed Web of Science ®Google Scholar
• CABALLERO T, LOPEZ-SERRANO C: Anaphylactic reaction and antibodies to DX-88 (kallikrein inhibitor) in a patient with hereditary angioedema. J. Allergy Clin. Immunol. (2006) 117(2):476-477.
   PubMed Web of Science ®Google Scholar
• WILLIAMS, T: DX-88, a novel recombinant protein inhibitor of plasma kallikrein: safety and immunogenicity in early studies. J. Allergy Clin. Immunol. (2005) 115:S181 (Abstract).
   Google Scholar
• BECK TR, BAIRD LG: Reply to: Anaphylactic reaction and antibodies to DX-88 (kallikrein inhibitor) in a patient with hereditary angioedema. J. Allergy Clin. Immunol. (2006) 117(2):477.
   PubMed Web of Science ®Google Scholar
• IMacKIE: DX-88 specificity and effects on activated contact factors. Unpublished Dyax internal data, on file (2005).
   Google Scholar